1 - 25 of 391 results for uniprot:Q9JLN9 in Computationally mapped citations
Results Customize
| Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Edinger A.L., Thompson C.B. Mol. Biol. Cell 13:2276-2288(2002) GeneRIF 56717 · Mapped (6) |
| BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., Sillaber C. Blood 100:3767-3775(2002) GeneRIF 56717 · Mapped (11) |
| TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. Jr. Cancer Cell 4:147-158(2003) GeneRIF 56717 · Mapped (15) |
| mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Kwon C.H., Zhu X., Zhang J., Baker S.J. Proc. Natl. Acad. Sci. U.S.A. 100:12923-12928(2003) GeneRIF 56717 · Mapped (7) |
| Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., Kwiatkowski D.J. J. Clin. Invest. 112:1223-1233(2003) GeneRIF 56717 · Mapped (29) |
| MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Gual P., Gremeaux T., Gonzalez T., Le Marchand-Brustel Y., Tanti J.F. Diabetologia 46:1532-1542(2003) GeneRIF 56717 MGI 1928394 · Mapped (11) |
| mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Hannan K.M., Brandenburger Y., Jenkins A., Sharkey K., Cavanaugh A., Rothblum L., Moss T., Poortinga G., McArthur G.A., Pearson R.B. et al. Mol. Cell. Biol. 23:8862-8877(2003) GeneRIF 56717 · Mapped (10) |
| Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Bliskovsky V., Ramsay E.S., Scott J., DuBois W., Shi W., Zhang S., Qian X., Lowy D.R., Mock B.A. Proc. Natl. Acad. Sci. U.S.A. 100:14982-14987(2003) GeneRIF 56717 MGI 1928394 · Mapped (7) |
| mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R. et al. Nat. Med. 10:594-601(2004) GeneRIF 56717 · Mapped (11) |
| Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. Hou L., Klann E. J. Neurosci. 24:6352-6361(2004) GeneRIF 56717 · Mapped (17) |
| mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., Yamanaka S. Mol. Cell. Biol. 24:6710-6718(2004) GeneRIF 56717 MGI 1928394 · Mapped (3) |
| Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. Latres E., Amini A.R., Amini A.A., Griffiths J., Martin F.J., Wei Y., Lin H.C., Yancopoulos G.D., Glass D.J. J. Biol. Chem. 280:2737-2744(2005) GeneRIF 56717 · Mapped (8) |
| Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Tremblay F., Gagnon A., Veilleux A., Sorisky A., Marette A. Endocrinology 146:1328-1337(2005) GeneRIF 56717 · Mapped (8) |
| The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. Corradetti M.N., Inoki K., Guan K.-L. J. Biol. Chem. 280:9769-9772(2005) GeneRIF 56717 · UniProtKB (4) · Mapped (15) |
| Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Ohanna M., Sobering A.K., Lapointe T., Lorenzo L., Praud C., Petroulakis E., Sonenberg N., Kelly P.A., Sotiropoulos A., Pende M. Nat. Cell Biol. 7:286-294(2005) GeneRIF 56717 · Mapped (25) |
| The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. Smith E.M., Finn S.G., Tee A.R., Browne G.J., Proud C.G. J. Biol. Chem. 280:18717-18727(2005) GeneRIF 56717 · Mapped (15) |
| Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. Chen J.K., Chen J., Neilson E.G., Harris R.C. J. Am. Soc. Nephrol. 16:1384-1391(2005) GeneRIF 56717 · Mapped (3) |
| Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells. Ohguchi K., Banno Y., Nakagawa Y., Akao Y., Nozawa Y. J. Cell. Physiol. 205:444-451(2005) GeneRIF 56717 · Mapped (12) |
| Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. Park I.H., Erbay E., Nuzzi P., Chen J. Exp. Cell Res. 309:211-219(2005) GeneRIF 56717 MGI 1928394 · Mapped (9) |
| mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Hu X., Pandolfi P.P., Li Y., Koutcher J.A., Rosenblum M., Holland E.C. Neoplasia 7:356-368(2005) GeneRIF 56717 · Mapped (14) |
| Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., Hay N. J. Biol. Chem. 280:32081-32089(2005) GeneRIF 56717 · Mapped (16) |
| Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Hiratani K., Haruta T., Tani A., Kawahara J., Usui I., Kobayashi M. Biochem. Biophys. Res. Commun. 335:836-842(2005) GeneRIF 56717 · Mapped (12) |
| Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. Lenz G., Avruch J. J. Biol. Chem. 280:38121-38124(2005) GeneRIF 56717 · Mapped (9) |
| Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Nat. Med. 12:122-127(2006) GeneRIF 56717 · Mapped (20) |
| Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Sakaguchi M., Isono M., Isshiki K., Sugimoto T., Koya D., Kashiwagi A. Biochem. Biophys. Res. Commun. 340:296-301(2006) GeneRIF 56717 · Mapped (3) |

